Kura Oncology, Inc. has announced upcoming presentations at the International Kidney Cancer Symposium (IKCS) Europe 2026, showcasing updated data from the ongoing FIT-001 clinical trial (NCT 06026410). The trial evaluates darlifarnib (KO-2806), a next-generation farnesyl transferase inhibitor (FTI), in combination with cabozantinib for patients with advanced clear cell renal cell carcinoma (ccRCC). This development builds on promising findings from the 2025 ESMO Congress, where the combination demonstrated notable clinical activity alongside a manageable safety profile.

The significance of these findings lies in darlifarnib’s potential to overcome resistance to VEGFR-targeted therapies, specifically cabozantinib, by inhibiting the farnesylation of RHEB and suppressing mTORC1 signaling. This mechanism could enhance the efficacy of existing targeted therapies, addressing a critical need in the treatment of ccRCC, particularly in patients who have previously been exposed to cabozantinib. The preliminary Phase 1 results presented at IKCS Europe 2026 will provide further insights into the therapeutic potential of this combination.

The implications for the field are substantial. By demonstrating the ability of darlifarnib to resensitize tumors to VEGFR TKI therapy, this research could shift current paradigms in ccRCC treatment, potentially accelerating the development timelines for combination therapies targeting resistant tumors. As Kura continues to explore the intersection of farnesyl transferase inhibition and targeted therapy, this work may pave the way for more effective treatment strategies in oncology, particularly for patients with advanced disease.

Source: globenewswire.com